Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A new government-funded study found that GLP-1 drugs slow the aging process in mice.
Novo Nordisk and Eli Lilly have received exciting news regarding their GLP-1 drugs. A recent study conducted on mice, funded by the National Institutes of Health, has shown that the drug semaglutide extended the lifespan of older, healthy mice by counteracting the effects of aging. Although calorie restriction is known to have anti-aging benefits, this study suggests that the effects of the GLP-1 drugs may go beyond just reducing caloric intake.
The study found that mice treated with semaglutide exhibited improved muscle and cognitive function, as well as reduced signs of aging such as increased inflammation and decreased regenerative capacity. Both Novo Nordisk, which manufactures semaglutide (Ozempic) and Wegovy, and Eli Lilly, which markets the GLP-1 drug tirzepatide (Mounjaro and Zepbound), stand to benefit from these findings.
The rapid growth of the GLP-1 drug market is evident, with Americans' use of GLP-1 injectables for weight loss nearly quadrupling since 2024. Currently, 11% of U.S. adults are taking these weight loss drugs, up from 3% just two years ago. J.P. Morgan Global Research forecasts that 25 million Americans will be on GLP-1 treatment by 2030, up from 10 million in 2024, and Morgan Stanley predicts the market for these drugs will more than double from 2025 to 2035, reaching $190 billion.
The positive news surrounding GLP-1 drugs is likely to encourage their adoption, benefiting both Novo Nordisk and Eli Lilly. While further research is needed to establish similar anti-aging effects in humans, the potential for these drugs to revolutionize health and well-being is immense.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
